Lipoprotein a: An emerging risk identifier and evolving clinical target

Abstract

Pathophysiology, epidemiology and genetics data support the causal role of Lipoprotein a, Lp(a), in cardiovascular disease, and in aortic valve calcification and stenosis. Increased levels of Lp(a) are the most prominent single gene lipid disorder worldwide since 1.4 billion people present Lp(a) values >30 mg/dL. Lp(a) associated risk becomes crucial in light of the emerging treatments currently underway for an effective reduction of its levels.

Keywords

• cardiovascular diseases
• lipoprotein a
• kringles
• antisense nucleotides therapy
• risk marker